The Experts below are selected from a list of 14043 Experts worldwide ranked by ideXlab platform
Marie Claire Laxenaire - One of the best experts on this subject based on the ideXlab platform.
-
iron therapy in iron deficiency anemia in pregnancy Intravenous Route versus oral Route
European Journal of Obstetrics & Gynecology and Reproductive Biology, 2005Co-Authors: Francoise Bayoumeu, Carole Subiranbuisset, Noureddine Baka, Henryse Legagneur, Patricia Monnierbarbarino, Marie Claire LaxenaireAbstract:Objective: The aim of this study was to compare Intravenous iron sucrose versus oral iron sulfate in anemia at 6 months of pregnancy. Study Design: A random prospective open study with individual benefit was performed involving 50 patients with hemoglobin levels between 8 and 10 g/dL and a ferritin value of <50 µg/L. In the Intravenous group (IV group) the iron dose was calculated from the following formula: Weight before pregnancy (kg) X (120 g/L - Actual hemoglobin [g/L]) X 0.24 + 500 mg. The oral group (PO group) received 240 mg of iron sulfate per day for 4 weeks. Treatment efficacy was assessed by measurement of hemoglobin and reticulocytes on days 8 15 21 and 30 and at delivery and of ferritin on day 30 and at delivery. The babys birth weight and iron stores were noted. Results were expressed as median ± interquartile range. Mann-Whitney and Wilcoxon tests were used for the analysis with P < .05 considered significant. Results: An increase in hemoglobin was observed rising from 9.6 ± 0.79 g/dL to 11.11 ± 1.3 g/dL on day 30 in the IV group and from 9.7 ± 0.5 g/dL to 11 ± 1.25 g/dL on day 30 in the PO group (not significant). On day 30 (P < .0001) and at delivery (P = .01) ferritin was higher in the IV group. A mean higher birth weight of 250 g was noted in the IV group (not significant). Conclusion: Iron sucrose appears to be a treatment without serious side effects indicated in correction of pregnancy anemia or iron stores depletion. (authors)
-
iron therapy in iron deficiency anemia in pregnancy Intravenous Route versus oral Route
American Journal of Obstetrics and Gynecology, 2002Co-Authors: Francoise Bayoumeu, Carole Subiranbuisset, Noureddine Baka, Henryse Legagneur, Patricia Monnierbarbarino, Marie Claire LaxenaireAbstract:Abstract OBJECTIVE: The aim of this study was to compare Intravenous iron sucrose versus oral iron sulfate in anemia at 6 months of pregnancy. STUDY DESIGN: A random, prospective, open study with individual benefit was performed involving 50 patients with hemoglobin levels between 8 and 10 g/dL and a ferritin value of P RESULTS: An increase in hemoglobin was observed, rising from 9.6 ± 0.79 g/dL to 11.11 ± 1.3 g/dL on day 30 in the IV group and from 9.7 ± 0.5 g/dL to 11 ± 1.25 g/dL on day 30 in the PO group (not significant). On day 30 ( P P =.01) ferritin was higher in the IV group. A mean higher birth weight of 250 g was noted in the IV group (not significant). CONCLUSION: Iron sucrose appears to be a treatment without serious side effects indicated in correction of pregnancy anemia or iron stores depletion. (Am J Obstet Gynecol 2002;186:518-22.)
Lorne F. Erdile - One of the best experts on this subject based on the ideXlab platform.
-
Safety and immunogenicity of ALVAC wild-type human p53 (vCP207) by the Intravenous Route in rhesus macaques.
Vaccine, 2001Co-Authors: Brigitte Rosenwirth, Eva-maria Kuhn, Jonathan L. Heeney, Christian Hurpin, James Tartaglia, Marie-claude Bonnet, Philippe Moingeon, Lorne F. ErdileAbstract:Abstract p53 is over-expressed in ∼50% of human cancers, and transfer of cytotoxic T lymphocytes (CTL) against wild-type p53 protects mice against p53-over-expressing tumors, suggesting that p53 might be an attractive target for immunotherapy. Immunization of mice with a recombinant canarypox virus, ALVAC, expressing human wild-type p53 (vCP207) prevented growth of p53-over-expressing tumors. Since Intravenous administration induced better immune responses in mice than other Routes, we have proposed to use this Route in cancer patients. However, because this vector has never been administered Intravenously to humans, and because of the possibility of inducing auto-immunity to a self-antigen, we felt it was necessary to first evaluate safety in rhesus macaques. We found that three Intravenous administrations of vCP207 at proportional doses up to 10× those proposed for humans produced no abnormalities in hematologic or clinical chemistry parameters. Serologic markers of autoimmunity and inflammation were unaffected, despite the >95% amino acid identity between human and rhesus p53. Pathological examination of numerous tissues yielded findings comparable to those in animals given placebo. Some animals showed anti-p53 antibody responses following vaccination, indicating that tolerance could be broken to some extent. However, with the exception of one animal with a possible delayed type hypersensitivity reaction to p53 protein, we did not see evidence for a cell-mediated response. The safety profile in monkeys with ALVAC-p53 provides encouragement for using such live, modified vectors via the Intravenous Route for human immunotherapy.
-
Safety and immunogenicity of ALVAC wild-type human p53 (vCP207) by the Intravenous Route in rhesus macaques.
Vaccine, 2001Co-Authors: Brigitte Rosenwirth, Eva-maria Kuhn, Jonathan L. Heeney, Christian Hurpin, James Tartaglia, Marie-claude Bonnet, Philippe Moingeon, Lorne F. ErdileAbstract:p53 is over-expressed in approximately 50% of human cancers, and transfer of cytotoxic T lymphocytes (CTL) against wild-type p53 protects mice against p53-over-expressing tumors, suggesting that p53 might be an attractive target for immunotherapy. Immunization of mice with a recombinant canarypox virus, ALVAC, expressing human wild-type p53 (vCP207) prevented growth of p53-over-expressing tumors. Since Intravenous administration induced better immune responses in mice than other Routes, we have proposed to use this Route in cancer patients. However, because this vector has never been administered Intravenously to humans, and because of the possibility of inducing auto-immunity to a self-antigen, we felt it was necessary to first evaluate safety in rhesus macaques. We found that three Intravenous administrations of vCP207 at proportional doses up to 10x those proposed for humans produced no abnormalities in hematologic or clinical chemistry parameters. Serologic markers of autoimmunity and inflammation were unaffected, despite the >95% amino acid identity between human and rhesus p53. Pathological examination of numerous tissues yielded findings comparable to those in animals given placebo. Some animals showed anti-p53 antibody responses following vaccination, indicating that tolerance could be broken to some extent. However, with the exception of one animal with a possible delayed type hypersensitivity reaction to p53 protein, we did not see evidence for a cell-mediated response. The safety profile in monkeys with ALVAC-p53 provides encouragement for using such live, modified vectors via the Intravenous Route for human immunotherapy.
Francoise Bayoumeu - One of the best experts on this subject based on the ideXlab platform.
-
iron therapy in iron deficiency anemia in pregnancy Intravenous Route versus oral Route
European Journal of Obstetrics & Gynecology and Reproductive Biology, 2005Co-Authors: Francoise Bayoumeu, Carole Subiranbuisset, Noureddine Baka, Henryse Legagneur, Patricia Monnierbarbarino, Marie Claire LaxenaireAbstract:Objective: The aim of this study was to compare Intravenous iron sucrose versus oral iron sulfate in anemia at 6 months of pregnancy. Study Design: A random prospective open study with individual benefit was performed involving 50 patients with hemoglobin levels between 8 and 10 g/dL and a ferritin value of <50 µg/L. In the Intravenous group (IV group) the iron dose was calculated from the following formula: Weight before pregnancy (kg) X (120 g/L - Actual hemoglobin [g/L]) X 0.24 + 500 mg. The oral group (PO group) received 240 mg of iron sulfate per day for 4 weeks. Treatment efficacy was assessed by measurement of hemoglobin and reticulocytes on days 8 15 21 and 30 and at delivery and of ferritin on day 30 and at delivery. The babys birth weight and iron stores were noted. Results were expressed as median ± interquartile range. Mann-Whitney and Wilcoxon tests were used for the analysis with P < .05 considered significant. Results: An increase in hemoglobin was observed rising from 9.6 ± 0.79 g/dL to 11.11 ± 1.3 g/dL on day 30 in the IV group and from 9.7 ± 0.5 g/dL to 11 ± 1.25 g/dL on day 30 in the PO group (not significant). On day 30 (P < .0001) and at delivery (P = .01) ferritin was higher in the IV group. A mean higher birth weight of 250 g was noted in the IV group (not significant). Conclusion: Iron sucrose appears to be a treatment without serious side effects indicated in correction of pregnancy anemia or iron stores depletion. (authors)
-
iron therapy in iron deficiency anemia in pregnancy Intravenous Route versus oral Route
American Journal of Obstetrics and Gynecology, 2002Co-Authors: Francoise Bayoumeu, Carole Subiranbuisset, Noureddine Baka, Henryse Legagneur, Patricia Monnierbarbarino, Marie Claire LaxenaireAbstract:Abstract OBJECTIVE: The aim of this study was to compare Intravenous iron sucrose versus oral iron sulfate in anemia at 6 months of pregnancy. STUDY DESIGN: A random, prospective, open study with individual benefit was performed involving 50 patients with hemoglobin levels between 8 and 10 g/dL and a ferritin value of P RESULTS: An increase in hemoglobin was observed, rising from 9.6 ± 0.79 g/dL to 11.11 ± 1.3 g/dL on day 30 in the IV group and from 9.7 ± 0.5 g/dL to 11 ± 1.25 g/dL on day 30 in the PO group (not significant). On day 30 ( P P =.01) ferritin was higher in the IV group. A mean higher birth weight of 250 g was noted in the IV group (not significant). CONCLUSION: Iron sucrose appears to be a treatment without serious side effects indicated in correction of pregnancy anemia or iron stores depletion. (Am J Obstet Gynecol 2002;186:518-22.)
Brigitte Rosenwirth - One of the best experts on this subject based on the ideXlab platform.
-
Safety and immunogenicity of ALVAC wild-type human p53 (vCP207) by the Intravenous Route in rhesus macaques.
Vaccine, 2001Co-Authors: Brigitte Rosenwirth, Eva-maria Kuhn, Jonathan L. Heeney, Christian Hurpin, James Tartaglia, Marie-claude Bonnet, Philippe Moingeon, Lorne F. ErdileAbstract:Abstract p53 is over-expressed in ∼50% of human cancers, and transfer of cytotoxic T lymphocytes (CTL) against wild-type p53 protects mice against p53-over-expressing tumors, suggesting that p53 might be an attractive target for immunotherapy. Immunization of mice with a recombinant canarypox virus, ALVAC, expressing human wild-type p53 (vCP207) prevented growth of p53-over-expressing tumors. Since Intravenous administration induced better immune responses in mice than other Routes, we have proposed to use this Route in cancer patients. However, because this vector has never been administered Intravenously to humans, and because of the possibility of inducing auto-immunity to a self-antigen, we felt it was necessary to first evaluate safety in rhesus macaques. We found that three Intravenous administrations of vCP207 at proportional doses up to 10× those proposed for humans produced no abnormalities in hematologic or clinical chemistry parameters. Serologic markers of autoimmunity and inflammation were unaffected, despite the >95% amino acid identity between human and rhesus p53. Pathological examination of numerous tissues yielded findings comparable to those in animals given placebo. Some animals showed anti-p53 antibody responses following vaccination, indicating that tolerance could be broken to some extent. However, with the exception of one animal with a possible delayed type hypersensitivity reaction to p53 protein, we did not see evidence for a cell-mediated response. The safety profile in monkeys with ALVAC-p53 provides encouragement for using such live, modified vectors via the Intravenous Route for human immunotherapy.
-
Safety and immunogenicity of ALVAC wild-type human p53 (vCP207) by the Intravenous Route in rhesus macaques.
Vaccine, 2001Co-Authors: Brigitte Rosenwirth, Eva-maria Kuhn, Jonathan L. Heeney, Christian Hurpin, James Tartaglia, Marie-claude Bonnet, Philippe Moingeon, Lorne F. ErdileAbstract:p53 is over-expressed in approximately 50% of human cancers, and transfer of cytotoxic T lymphocytes (CTL) against wild-type p53 protects mice against p53-over-expressing tumors, suggesting that p53 might be an attractive target for immunotherapy. Immunization of mice with a recombinant canarypox virus, ALVAC, expressing human wild-type p53 (vCP207) prevented growth of p53-over-expressing tumors. Since Intravenous administration induced better immune responses in mice than other Routes, we have proposed to use this Route in cancer patients. However, because this vector has never been administered Intravenously to humans, and because of the possibility of inducing auto-immunity to a self-antigen, we felt it was necessary to first evaluate safety in rhesus macaques. We found that three Intravenous administrations of vCP207 at proportional doses up to 10x those proposed for humans produced no abnormalities in hematologic or clinical chemistry parameters. Serologic markers of autoimmunity and inflammation were unaffected, despite the >95% amino acid identity between human and rhesus p53. Pathological examination of numerous tissues yielded findings comparable to those in animals given placebo. Some animals showed anti-p53 antibody responses following vaccination, indicating that tolerance could be broken to some extent. However, with the exception of one animal with a possible delayed type hypersensitivity reaction to p53 protein, we did not see evidence for a cell-mediated response. The safety profile in monkeys with ALVAC-p53 provides encouragement for using such live, modified vectors via the Intravenous Route for human immunotherapy.
Anthony Smithyman - One of the best experts on this subject based on the ideXlab platform.
-
safety and efficacy of phage therapy via the Intravenous Route
Fems Microbiology Letters, 2016Co-Authors: Peter Speck, Anthony SmithymanAbstract:Increasing development of antimicrobial resistance is driving a resurgence in interest in phage therapy: the use of bacteriophages to treat bacterial infections. As the lytic action of bacteriophages is unaffected by the antibiotic resistance status of their bacterial target it is thought that phage therapy may have considerable potential in the treatment of a wide range of topical and localized infections. As yet this interest has not extended to Intravenous (IV) use, which is surprising given that the historical record shows that phages are likely to be safe and effective when delivered by this Route. Starting almost 100 years ago, phages were administered Intravenously in treatment of systemic infections including typhoid, and Staphylococcal bacteremia. There was extensive IV use of phages in the 1940s to treat typhoid, reportedly with outstanding efficacy and safety. The safety of IV phage administration is also underpinned by the detailed work of Ochs and colleagues in Seattle who have over 4 decades experience with IV injection into human subjects of large doses of highly purified coliphage PhiX174. Though these subjects included a large number of immune deficient children no serious side effects were observed over this extended time period. The large and continuing global health problems of typhoid and Staphylococcus aureus are exacerbated by the increasing antibiotic resistance of these pathogens. We contend that these infections are excellent candidates for use of Intravenous phage therapy.
